Lupin to acquire two inhalation brands from Sunovion Pharma for US$ 75 million
Global pharmaceutical major Lupin Limited announced signing of an agreement to acquire all rights to two inhalation medicines, Brovana (arformoterol tartrate) inhalation solution and Xopenex HFA (levalbuterol tartrate) inhalation aerosol, from Sunovion Pharmaceuticals Inc. for a purchase price of US$ 75 million. Lupin expects the transaction to be accretive to earnings in the first year.
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the US and strengthens the company
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!